By bridging insights from the renal, vascular and immune systems, we position Nogo-B as an emerging contributor to blood pressure regulation and highlight its potential both as a biomarker for vascular dysfunction and as a therapeutic target in salt-sensitive and treatment-resistant hypertension. This evidence concerns the gene RTN4 and treatment-resistant hypertension.